

Anti- CCP Ab Test

ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY TEST

A HIGHLY SPECIFIC DIAGNOSTIC, PROGNOSTIC AND PREDICTIVE TEST FOR RHEUMATOID ARTHRITIS.

Rheumatoid arthritis challenges

Early diagnosis & Early intervention

Required:

A Statistically significant Test for RA with higher Specificity, PPV(Positive predictive value), LR* (Likelihood ratio)than RF test in a clinically diverse population.

**LR is defined as the ratio of the probabilities of a particular test result among patients with and without disease in early and undifferentiated arthritis.*

Anti-CCP Ab Assay: Clinical Utility

Diagnosis of rheumatoid arthritis and prediction of disease severity

Particularly during the early phases of the disease when making a definitive diagnosis on clinical grounds may be difficult.

Early RA, <i>n</i> =40	Anti-CCP		RF		<i>P</i> values	95% CI
	<i>n</i> =40, ERA ^a	<i>n</i> =404, nERA ^a	<i>n</i> =40, ERA ^a	<i>n</i> =404, nERA ^a		
Sensitivity	62%		57%		0.69	−9.4 to 19.4
Specificity	96%		90%		<0.001	2.8 to 9.6
Positive predictive value	62%		36%		<0.001	13.6 to 38.4
Negative predictive value	96%		95%		0.92	−4.8 to 6.8
Positive likelihood ratio	16.8		5.8		–	–
Negative likelihood ratio	0.4		0.5		–	–
Pretest probability	9%		9%		–	–

Tests properties of anti-CCP antibodies and RF in 40 early-RA patients (ERA) and controls (nERA)

^a ERA and n ERA groups had less than 2 years of rheumatic symptoms.

Recently anti-CCP testing has become substantial part of ACR-EULAR classification criteria for RA.

2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

Diagnostic marker for Rheumatoid Arthritis with a specificity of >98% and sensitivity of 70%.

Differentiates Rheumatoid Arthritis from recent onset undifferentiated arthritis thus allowing accurate prediction of a substantial number of patients who will fulfil the ACR criteria for RA.

Positive in 40% of patients who test negative for Rheumatoid Factor.

Predicts erosive joint disease

Antedates clinical arthritis by an average of 5 years.

Useful for monitoring treatment response.

TEST DETAILS

Technology

CLIA

Starting Material

2 ml of Serum

Result & Interpretation
